COVID And Medicare: Pricing Restraints Needed For Part B Vaccines, MedPAC Panelists Say
GSK’s blockbuster Shingrix and other Part D vaccines would be switched to Part B under proposal being developed by influential advisory commission. Lack of pricing controls in Part B is generating concerns among panelists, though, as MedPAC aims to finalize its recommendations on revising Medicare reimbursement for vaccines by next spring.
You may also be interested in...
CMS will allow Part D vaccine administration to be billed and reimbursed separately from product costs in 2008, the agency states in guidance to Medicare drug plan sponsors issued May 14
Physician administration of Part D vaccines will be covered under Medicare Part B during 2007 and under Part D in 2008 and thereafter, under broad tax and health care legislation (HR 6111) signed into law by President George Bush Dec. 20
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.